University of Michigan

The Brigham and Women's Hospital, Inc.

Exact Sciences Development Company, LLC

Armune Biosciences, Inc.

Metabolon, Inc.

Arul M Chinnaiyan

Scott Tomlins

Mark A Rubin

Rohit Mehra

Xiaoju Wang

Francesca Demichelis

Daniel Rhodes

Sven Perner

Xiao-Wei Sun

Irfan A Asangani

Dan Robinson

Shaomeng Wang

Duxin Sun

Kay A Lawton

Charles Lee

Liu Liu

Donna McEachern

Ruijuan Luo

Chao-Yie Yang

Matthew W Mitchell

Alvin Berger

Longchuan Bai

Bing Zhou

Jeanne Stuckey

Yujun Zhao

Jennifer Lynn Meagher

Xu Ran

Matthew Iyer

John Prensner

Nallasivam Palanisamy

Yi-Mi Wu

Jindan Yu

Shanker Kalyana-Sundaram

Saravana Mohan Dhanasekaran

Arun Sreekumar

Angelo Aguilar

Xiaoqin Li

David G Beer

Yang Hu

Hacer Karatas

Guoan Chen

Alex Tsodikov

Marcin Cieslik

Jeanne Ohrnberger

Bo Wen

Ting Zhao

Xiaosong Wang

Ram Shankar Mani

Qi Cao

Megan Lim

Kojo Elenitoba-Johnson

Felix Y Feng

Thirunavukkarasu Velusamy

Rohit Malik

Yajia Zhang

Sethuramasundaram Pitchiaya

Yashar Niknafs

Bo Han

Chandan Kumar

Yasuyuki Hosono

Anagh Sahasrabuddhe

Sooryanaryana Lnu

Sooryanarayana Lnu

Bharathi Laxman

Christopher Beecher

Daniel R Rhodes

Xiao-Song Wang

Scott A Tomlins

Sooryanarayana Varambally

The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ncRNAs as diagnostic markers and clinical targets for prostate, lung, breast and pancreatic cancer.

NcRNA and uses thereof

Provided herein are compositions and methods for treating cancer. In particular, provided herein are compositions, methods, and uses of targeted therapy to treat cancer (e.g., prostate cancer) in subjects with CDK12 mutations.

Compositions and methods for treating cancer

The present disclosure relates to methods of determining a treatment course of action. In particular, the present disclosure relates to mutations in the gene encoding estrogen receptor and their association with responsiveness to estrogen therapies for cancer.

Systems and methods for determining a treatment course of action

ncRNA and uses thereof

The present disclosure provides compositions and methods for using one or more polypeptide probes to profile an immune response. The polypeptide probe can be used to detect one or more antibodies from a sample. Furthermore, the present disclosure provides methods and compositions for characterizing a cancer based on the detection of one or more antibodies, such as autoantibodies.

Using phage epitopes to profile the immune response

Provided herein are compositions and methods for treating cancer. In particular, provided herein are compositions, methods, and uses of inhibitors of ARlnc1 for treating cancer.

The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to RAF gene fusions as diagnostic markers and clinical targets for cancer.

RAF gene fusions

Provided herein are compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, provided herein are non-coding RNAs as diagnostic markers and clinical targets for cancer.

Non-coding RNAS and uses thereof

Provided herein are compositions and methods for treating cancer. In particular, provided herein are compositions, methods, and uses of inhibitors of THOR for treating cancer.

The present disclosure relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present disclosure relates to recurrent gene fusions as clinical targets for cancer.

ERG targeted therapy

Schlap-1 ncRNA and uses thereof

Inhibitors of BET bromodomains and compositions containing the same are disclosed. Methods of using the BET bromodomain inhibitors in the treatment of diseases and conditions wherein inhibition of BET bromodomain provides a benefit, like cancers, also are disclosed.

BET bromodomain inhibitors and therapeutic methods using the same

The present disclosure provides substituted 9H-pyrimido[4,5-b]indoles and 5H-pyrido[4,3-b]indoles and related analogs represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R, A, B, B, G, X, Y, Y, and Yare as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a condition or disorder responsive to inhibition of BET bromodomains. Compounds of the present disclosure are especially useful for treating cancer.

9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors

Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.

Recurrent gene fusions in prostate cancer

Growing community of inventors

Plymouth, MI, United States of America

Arul M Chinnaiyan